Potential Trial for Huntington's
Over a year ago I signed up to receive information about any Huntington’s trials that might be going on. I just got an email for a trial that is looking for participants. I don’t fit the criteria, nor am I close enough to any of the nine locations, but I thought I should share the information here!
HDtrials.org
Reach2HD is a Phase 2 study to determine the safety, tolerability and efficacy of PBT2 in patients with early to mid-stage Huntington’s disease currently recruiting participants.
Research has shown that normally occurring metals in the brain play a significant role in diseases such as HD. PBT2 has been demonstrated to interrupt interactions between biological metals and target proteins in the brain to prevent the deterioration of brain cells in animal models and Alzheimer’s patients, therefore it may improve cognition.
Locations: Nine (currently)) Research Centers in the United States. (See list and contact information below).
Participants: A total of 100 participants are needed.
• Age: 25 or older
• Early to mid-HD, with a genetic test CAG repeat equal or greater than 36, motor symptoms of HD and a Total Functional Capacity Subscale Score (TFC) between 6 and 13
• Have a cognitive impairment as demonstrated by a MoCa score of equal or greater than 12
• Each participant must have a study partner who is willing to provide consent and spends on average at least 2 hours a day for at least four days a week with the patient and agrees to attend certain visits and provide accurate information about the patient.
• Participants must be able to swallow oral capsules, and if they are taking tetrabenazine, must have been on a stable dose for at least 3 months.
• Participants may not have an allergy to PBT2 or other primary neurodegenerative disorders association with dementia, or any other condition that may impair cognition. They may not have chronic heart, kidney, blood, liver conditions, or have been diagnosed with a malignancy within 2 years of screening. Pregnant or lactating females may not participate as well.
Trial Duration: 34 weeks and a total of 8 participant visits including a final follow-up visit. At these visits there will be blood drawn and other tests performed, and at three there will be an eye exam. Study partners will be required to attend 3 visits with the participant.
There are travel reimbursements available for participants. Please speak to the site coordinator about details.
For more details please call one of the participating sites and please tell the coordinator that you learned about the study through HDTrials.org. For more information regarding this study please visit: http://www.clinicaltrials.gov/ct2/show/NCT01590888? term=Reach2hd&rank=1
Locations (as of this date – we will notify you of new sites going online or you can check at:
http://www.huntington-study-group.org/HSGResearch/ClinicalTrialsObservationalStudiesinProgress/Reach2HD/tabid/243/Default.aspx
United States, California
University of California San Diego
San Diego, California, United States, 92161
Jody Goldstein: 858-246-1254
United States, Colorado
Colorado Neurological Institute
Englewood, Colorado, United States, 80113
Diane Erickson: 303-762-6674
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States
Nadine Yoritomo 410-614-9254
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
Samantha Gibson: 410-328-4349
United States, Minnesota
Struthers Parkinson’s Center
Golden Valley, Minnesota, United States, 55427
Patricia Edo: 952-993-5495
United States, Missouri
Washington University
St. Louis, Missouri, United States, 63110
Patricia Deppen: 314-362-8548
United States, New York
Albany Medical College
Albany, New York, United States, 12208
Mary Eglow: 518-262-6611
Columbia University Medical Center
New York City, New York, United States, 10032
Ronda Couse: 212-305-2387
United States, Tennessee
University of Tennessee Health Science Center
Memphis, Tennessee, United States, 38163
Kate Marshall: 901-448-6180